Welcome to our dedicated page for Penumbra news (Ticker: PEN), a resource for investors and traders seeking the latest updates and insights on Penumbra stock.
Penumbra, Inc. (NYSE: PEN) is described in its public communications as the world’s leading thrombectomy company, with a portfolio focused on computer assisted vacuum thrombectomy (CAVT™) and related devices for serious vascular and neurovascular conditions. The Penumbra news feed on this page aggregates company announcements, clinical trial updates and capital markets communications that shape how investors and clinicians follow the PEN stock story.
Recent news includes the announcement of a definitive Agreement and Plan of Merger with Boston Scientific Corporation, under which a Boston Scientific subsidiary will merge with and into Penumbra, leaving Penumbra as a wholly owned subsidiary if the transaction closes. The joint press release details the planned cash-and-stock consideration and notes that, upon completion, Penumbra’s securities are expected to be delisted from the New York Stock Exchange and deregistered under the Securities Exchange Act of 1934.
Beyond M&A developments, Penumbra’s news flow features earnings releases and preliminary financial updates furnished via Form 8-K, outlining revenue trends, margins and non-GAAP measures such as constant currency revenue and adjusted EBITDA. These items provide context on the company’s operating performance and financial outlook as it continues to develop and commercialize thrombectomy and embolization technologies.
Penumbra also issues news around clinical research milestones. Notable examples include results from the pivotal STORM-PE randomized controlled trial, which evaluated CAVT using Penumbra’s Lightning Flash™ plus anticoagulation versus anticoagulation alone in acute intermediate-high risk pulmonary embolism. Company press releases describe superior reductions in right heart strain, thrombus burden and improvements in functional outcomes for patients treated with CAVT plus anticoagulation, with comparable safety profiles between treatment arms.
Additional news items cover leadership changes and investor relations activities, such as the appointment of a new company president and scheduled presentations at healthcare and investor conferences, including the J.P. Morgan Healthcare Conference and other sector events. These updates highlight how Penumbra’s management communicates with the investment community and discusses its clinical and commercial strategy.
By following this PEN news page, readers can review a consolidated stream of Penumbra’s press releases, transaction announcements, clinical trial disclosures and financial updates, all of which are sourced from official company communications and SEC-related materials.
Penumbra, Inc. (NYSE: PEN) will present at the Bank of America Securities 2022 Healthcare Conference on May 10, 2022, at 4:40 PM PT / 7:40 PM ET. The event will provide insights into the company's innovative healthcare solutions and strategies. A webcast of the presentation will be available on Penumbra's website for two weeks post-event. Headquartered in Alameda, California, Penumbra designs and markets therapies addressing significant medical needs globally.
Penumbra, Inc. (NYSE: PEN) has launched its advanced Indigo Aspiration System technologies, Lightning 7 and Lightning 12, in Europe following CE Mark approval. These systems, focused on mechanical thrombectomy for removing blood clots in a single session, aim to enhance patient outcomes by differentiating between clot and blood to minimize blood loss. Physicians in Europe now have access to this innovative technology, which has already shown success in the U.S. market, potentially reducing ICU stays and improving care efficiency.
Penumbra, Inc. (NYSE: PEN) will host a conference call on May 3, 2022, at 4:30 PM ET to discuss its first-quarter 2022 financial results. A press release detailing these results will be issued after market close that day. Investors can access the call through a phone line or via a webcast on the company's website. Penumbra focuses on innovative healthcare solutions and operates in over 100 countries, creating products that address significant medical needs.
Penumbra, Inc. (NYSE: PEN) has launched the REAL Immersive System y-Series, expanding its virtual reality healthcare platform. This new offering enhances patient care with upgraded hardware and a broader activity library for rehabilitation therapy. The platform now addresses conditions affecting over 50 million patients in the U.S. The improved interface, TherapyView™, allows clinicians to customize therapy programs, engaging patients more effectively. The y-Series was showcased at the American Occupational Therapy Association Annual Conference in San Antonio, TX.
Penumbra, Inc. (NYSE: PEN) is set to present at the 21st Annual Needham Virtual Healthcare Conference on April 11, 2022, at 3:00 PM ET. The event will showcase Penumbra's innovative therapies and its commitment to addressing challenging medical conditions.
Investors can access the presentation via a webcast on the company's website, available for two weeks post-event. Penumbra operates globally, supporting healthcare providers in over 100 countries with a robust portfolio aimed at significant unmet medical needs.
Penumbra, Inc. (NYSE: PEN) reported financial results for Q4 and full year 2021, with Q4 revenue reaching $204.0 million, a 22.2% increase from Q4 2020. Full year revenue totaled $747.6 million, up 32.6% year-over-year. US revenue represented 71% of total revenue, with vascular products growing 30.4% to $113.6 million in Q4. Despite higher operating expenses, non-GAAP operating income was $2.5 million for Q4. The company forecasts 2022 revenue between $860 million and $875 million, indicating 15% to 17% growth.
Penumbra, Inc. (NYSE: PEN) is set to present at Citi's 2022 Virtual Healthcare Conference on February 24, 2022, at 1:15 PM ET.
Investors can access the presentation via a webcast on the company's website, which will remain available for at least two weeks after the event. Penumbra, headquartered in Alameda, California, specializes in innovative healthcare therapies and serves clients in over 100 countries. For further details, visit www.penumbrainc.com.
Penumbra, Inc. (NYSE: PEN) has announced a conference call to discuss its financial results for the fourth quarter and full year of 2021. The call is scheduled for February 22, 2022, at 4:30 PM Eastern Time, following a press release detailing the financial results. This event will be accessible via phone and webcast, with the latter available on the company's website for two weeks post-call.
Penumbra focuses on innovative therapies and has a global presence, supporting healthcare providers across more than 100 countries.
Penumbra, Inc. (NYSE: PEN) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022. The management team will present at 11:15 AM ET (8:15 AM PT). Interested investors can access an audio webcast of the presentation through the company's website, available for at least two weeks post-event. Penumbra is dedicated to innovative healthcare solutions, serving providers in over 100 countries.
Penumbra, Inc. (NYSE: PEN) announced positive results from the CHEETAH clinical study of its CAT RX Catheter at the TCT conference. The study achieved high rates of blood clot removal and restored blood flow in patients with high thrombus burden. Key findings included a 99.5% reduction in TIMI thrombus grade and 97.5% of patients achieving TIMI flow grade 3 post-treatment. No serious device-related adverse events were reported. The study emphasizes the effectiveness and safety of continuous powered aspiration thrombectomy in acute coronary syndrome interventions.
FAQ
What is the current stock price of Penumbra (PEN)?
What is the market cap of Penumbra (PEN)?
